Skip to content
CancerIndex

Publication

Repurposing the Neurokinin-1 receptor antagonist Aprepitant to eradicate relapsed/refractory acute lymphoblastic leukemia via mitochondria-driven necroptosis.

Gang Shao, Hanling Pan, Jiayi Zhu, Nanfang Zhuo, Xurui Cheng, Hongzhang Wu, Ruitao Xiao, Xiangyu Hong, Jianhu Li, Junjie Ma, Xiangmin Tong, Huafeng Wang, Xi Wang, Caiyun Fu

Cancer lettersSep 28, 2026PMID 42184918doi:10.1016/j.canlet.2026.218621 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 29, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260929-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

The prognosis for relapsed/refractory acute lymphoblastic leukemia (R/R ALL) remains dismal due to intrinsic and acquired chemoresistance, highlighting an urgent need for novel therapeutic strategies. The neurokinin-1 receptor (NK-1R) represents an emerging oncological target, yet its role and…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.